Evidence map›Paper›PMID 41080363›Full record

ArticleCureus2025

Incidence and Factors Influencing Locomotive Syndrome in Cancer Patients Living in the Community.

Yoshiteru Akezaki, Eiji Nakata, Masato Kikuuchi, Yoshimi Katayama, Shinsuke Sugihara

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yoshiteru AkezakiDivision of Physical Therapy, Kochi Professional University of Rehabilitation, Tosa, JPN.
Eiji NakataDepartment of Orthopaedic Surgery, Okayama University Hospital, Okayama, JPN.
Masato KikuuchiDepartment of Rehabilitation Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama, JPN.
Yoshimi KatayamaDepartment of Rehabilitation Medicine, Okayama University Hospital, Okayama, JPN.
Shinsuke SugiharaDepartment of Rehabilitation Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Investigating locomotive syndrome (LS) of cancer survivors in the community will help clarify the importance of rehabilitation for cancer survivors in the community and provide a basis for exploring effective interventions. The primary purpose of this study was to conduct a comparison of LS, fatigue, psychological problems, and physical activity in cancer survivors and those without cancer in the community. The secondary purpose was to analyze factors influencing LS in cancer patients. Methods The study involved 59 cancer patients undergoing chemotherapy at home and 59 people without cancer. The cancer patients were those undergoing chemotherapy as outpatients and constituted the cancer group. The non-cancer people were living in the community and constituted the non-cancer group. Cancer and non-cancer groups were surveyed and measured for LS, fatigue, psychological problems, and physical activity. The cancer group was also surveyed for the duration of chemotherapy treatment and the presence or absence of bone metastases. Results The cancer group was significantly more likely than the non-cancer group to have LS stage 2, to have fatigue, and to have psychological problems. Fatigue and psychological problems were significantly associated with LS stage 2. Conclusions Cancer patients in the community need to be assessed regularly by healthcare providers and interventions should be made according to their condition.

Indexed as

cancerchemotherapyfactorlocomotive syndromerehabilitation

Identifiers

PMID41080363
PMCPMC12507503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.